K
King Tan
Researcher at BC Cancer Agency
Publications - 34
Citations - 3524
King Tan is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 19, co-authored 32 publications receiving 3020 citations. Previous affiliations of King Tan include University of British Columbia.
Papers
More filters
Journal ArticleDOI
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson,Graham W. Slack,Kerry J. Savage,Joseph M. Connors,Susana Ben-Neriah,Sanja Rogic,David W. Scott,King Tan,Christian Steidl,Laurie H. Sehn,Wing C. Chan,Javeed Iqbal,Paul N. Meyer,Georg Lenz,George E. Wright,Lisa M. Rimsza,Carlo Valentino,Patrick Brunhoeber,Thomas M. Grogan,Rita M. Braziel,James R. Cook,Raymond R. Tubbs,Dennis D. Weisenburger,Elias Campo,Andreas Rosenwald,German Ott,German Ott,Jan Delabie,Christina Holcroft,Elaine S. Jaffe,Louis M. Staudt,Randy D. Gascoyne +31 more
TL;DR: Assessment of MYC and BCL2 expression by IHC represents a robust, rapid, and inexpensive approach to risk-stratify patients with DLBCL at diagnosis.
Journal ArticleDOI
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
Robert Kridel,Robert Kridel,Barbara Meissner,Sanja Rogic,Merrill Boyle,Adele Telenius,Bruce Woolcock,Jay Gunawardana,Jay Gunawardana,Christopher R Jenkins,Chris Cochrane,Susana Ben-Neriah,King Tan,Ryan D. Morin,Stephen Opat,Laurie H. Sehn,Joseph M. Connors,Marco A. Marra,Andrew P. Weng,Christian Steidl,Christian Steidl,Randy D. Gascoyne,Randy D. Gascoyne +22 more
TL;DR: Recurrent NOTCH1 mutations are identified that provide the preclinical rationale for therapeutic inhibition of the NOTCH pathway in a subset of patients with MCL and are shown to reduce proliferation and induced apoptosis in 2 MCL cell lines.
Journal ArticleDOI
EZH2 mutations are frequent and represent an early event in follicular lymphoma
Csaba Bödör,Csaba Bödör,Vera Grossmann,Nikolay Popov,Jessica Okosun,Ciaran O'Riain,King Tan,Jacek Marzec,Shamzah Araf,Jun Wang,Abigail M. Lee,Andrew Clear,Silvia Montoto,Janet Matthews,Sameena Iqbal,Hajnalka Rajnai,Andreas Rosenwald,German Ott,German Ott,Elias Campo,Lisa M. Rimsza,Erlend B. Smeland,Erlend B. Smeland,Wing C. Chan,Rita M. Braziel,Louis M. Staudt,George E. Wright,T. Andrew Lister,Olivier Elemento,Robert Kerrin Hills,John G. Gribben,Claude Chelala,András Matolcsy,Alexander Kohlmann,Torsten Haferlach,Randy D. Gascoyne,Jude Fitzgibbon +36 more
TL;DR: Overall, the high incidence of EZH2 mutations in FL and their stability during disease progression makes FL an appropriate disease to evaluate EZh2 targeted therapy.
Journal ArticleDOI
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
David D.W. Twa,Fong Chun Chan,Fong Chun Chan,Susana Ben-Neriah,Bruce Woolcock,Anja Mottok,King Tan,Graham W. Slack,Jay Gunawardana,Raymond S. Lim,Andrew McPherson,Robert Kridel,Adele Telenius,David W. Scott,Kerry J. Savage,Sohrab P. Shah,Randy D. Gascoyne,Christian Steidl +17 more
TL;DR: It is suggested that recurrent genomic rearrangement events underlie an immune privilege phenotype in a subset of B-cell lymphomas, and novel translocations and chimeric fusion transcripts involving PDLs at base-pair resolution are characterized.
Journal ArticleDOI
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
King Tan,David W. Scott,Fangxin Hong,Brad S. Kahl,Richard I. Fisher,Nancy L. Bartlett,Ranjana H. Advani,Rena Buckstein,Lisa M. Rimsza,Joseph M. Connors,Christian Steidl,Leo I. Gordon,Sandra J. Horning,Randy D. Gascoyne +13 more
TL;DR: The prognostic significance of TAMs in locally extensive and advanced-stage CHL in a multicenter phase 3 randomized controlled clinical trial is demonstrated and increased CD68 or CD163 expression was significantly associated with inferior failure-free survival and OS.